References
- American Thoracic Society/European Respiratory Society Task Force2004Standards for the Diagnosis and Management of Patients with COPD [online] Version 1.2New YorkAmerican Thoracic SocietyAccessed 30 April 2006 URL: http://www.thoracic.org/copd/
- BourbeauJJulienMMaltaisF2003Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management interventionArch Intern Med1635859112622605
- [BTS] British Thoracic Society1997British Thoracic Society COPD guidelines summaryThorax52Suppl 51329039230
- BrownHPrescotRBarnettV1999Applied mixed models in medicineRepeated measures dataNew YorkJ Wiley and Sons199259
- BurgePSCalverleyPMJonesPW2000Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBr Med J320129730310807619
- CalverleyPMBoonsawatWCsekeZ2003aMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J229121914680078
- CalverleyPPauwelsRVestboJ2003bCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet3614495612583942
- CalverleyPMWalkerP2003Chronic obstructive pulmonary diseaseLancet36210536114522537
- CoxDR1972Regression models and life-tables (with discussion)J Royal Stat Soc Ser B34187220
- [GOLD] Global Initiative for Chronic Obstructive Lung Disease2005Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - updated 2005ModenaGlobal Initiative for Chronic Obstructive Lung Disease [online]Accessed 30 April 2006 URL: www.goldcopd.com
- HollanderMWolfeDAThe two-sample location problemNon-parametric statistical methods19736782New YorkJohn Wiley and Sons
- JonesPWQuirkFHBaveystockCM1992A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory QuestionnaireAm Rev Respir Dis145132171595997
- JonesPWWillitsLRBurgePS2003Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbationsEur Respir J21687312570111
- LehmannE1975Nonparametrics: statistical methods based on ranksSan FranciscoHolden-Day1327
- MahlerDAWeinbergDHWellsCK1984The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexesChest8575186723384
- MahlerDAWirePHorstmanD2002Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med16610849112379552
- [NICE] National Collaborating Centre for Chronic Conditions2004Chronic Obstructive Pulmonary Disease (NICE Guideline No. 12)Thorax59Suppl 11232
- O’DonnellDELamMWebbKA1999Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med160542910430726
- RothwellPM2005Treating individuals 2: subgroup analysis in randomised controlled trials: importance, indications, and interpretationLancet3651768615639301
- SpencerSCalverleyPMBurgePS2004Impact of preventing exacerbations on deterioration of health status in COPDEur Respir J2369870215176682
- SzafranskiWCukierARamirezA2003Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J21748112570112
- van ElterenP1960On the combination of independent two-sample tests of WilcoxonBull Int Statist Inst3735161
- VestboJ2004The TORCH (towards a revolution in COPD health) survival study protocolEur Respir J242061015332386